Protease-activatable organometal-peptide bioconjugates with enhanced cytotoxicity on cancer cells

Bioconjugate Chemistry

Volumn 21, Issue 7, 2010, Pages 1288-1296

  Splith, Katrin ^a   Hu, Wanning ^b   Schatzschneider, Ulrich ^b   Gust, Ronald ^c   Ott, Ingo ^d   Onambele, Liliane A ^f   Prokop, Aram ^e   Neundorf, Ines ^a  

^a Institut fur Biochemie   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^e Kinderchirurgische Klinik der Kinderklinik der Stadt Köln gGmbH   (Germany)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CATHEPSIN B; CYMANTERENE ARGINYLARGINYLGLYCYLLEUCYLARGINYLLYSYLARGINYLLEUCYLARGINYLLYSYLPHENYLALANYLARGINYLASPARAGINYLLYSYLISOLEUCYLLYSYLGLUTAMYLLYSINE; CYMANTERENE GLYCYLLEUCYLARGINYLLYSINE CYMANTERENE ARGINYLLEUCYLARGINYLLYSYLPHENYLALANYLARGINYLASPARAGINYLLYSYLISOLEUCYLLYSYLGLUTAMYLLYSINE; CYMANTERENE GLYCYLLEUCYLARGINYLLYSYLARGINYLLEUCYLARGINYLLYSYLPHENYLALANYLARGINYLASPARAGINYLLYSYLISOLEUCYLLYSYLGLUTAMYLLYSINE; CYMANTERENE GLYCYLPHENYLALANYLLEUCYLGLYCYLGLYCYLLEUCYLARGINYLLYSINE GLYCYLPHENYLALANYLLEUCYLGLYCINE CYMANTERENE ARGINYLLEUCYLARGINYLLYSYLPHENYLALANYLARGINYLASPARAGINYLLYSYLISOLEUCYLLYSYLGLUTAMYLGLYCINE; CYSTEINYLPHENYLALANINE CYMANTERENE ARGINYLLEUCYLARGINYLLYSYLPHENYLALANYLARGINYLASPARAGINYLLYSYLISOLEUCYLLYSYLGLUTAMYLPHENYLALANINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL; CELL STRAIN HT29; CELL STRAIN MCF 7; CELL TRANSPORT; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME ACTIVE SITE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

EID: 77954868297     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc100089z     Document Type: Article

References (54)

1. Storr, T., Thompson, K. H., and Orvig, C. (2006) Design of targeting ligands in medicinal inorganic chemistry Chem. Soc. Rev. 35, 534-544
2. Lippert, B. (1999) Cisplatin, Chemistry and Biochemistry of a Leading Anticancer Drug, Wiley-VCH, Weinheim, Germany.
3. Cossa, G., Gatti, L., Zunino, F., and Perego, P. (2009) Strategies to improve the efficacy of platinum compounds Curr. Med. Chem. 16, 2355-2365
4. Farrell, N., Ha, T. T., Souchard, J. P., Wimmer, F. L., Cros, S., and Johnson, N. P. (1989) Cytostatic trans-platinum(II) complexes J. Med. Chem. 32, 2240-2241
5. Jodrell, D. I., Evans, T. R., Steward, W., Cameron, D., Prendiville, J., Aschele, C., Noberasco, C., Lind, M., Carmichael, J., Dobbs, N., Camboni, G., Gatti, B., and De Braud, F. (2004) Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma Eur. J. Cancer 40, 1872-1877
6. Lovejoy, K. S., Todd, R. C., Zhang, S., McCormick, M. S., D'Aquino, J. A., Reardon, J. T., Sancar, A., Giacomini, K. M., and Lippard, S. J. (2008) cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects Proc. Natl. Acad. Sci. U.S.A. 105, 8902-8907
7. Hartinger, C. G., Zorbas-Seifried, S., Jakupec, M. A., Kynast, B., Zorbas, H., and Keppler, B. K. (2006) From bench to bedside - preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A) J. Inorg. Biochem. 100, 891-904
8. Alessio, E., Mestroni, G., Bergamo, A., and Sava, G. (2004) Ruthenium antimetastatic agents Curr. Top. Med. Chem. 4, 1525-1535
9. Michard, Q., Jaouen, G., Vessieres, A., and Bernard, B. A. (2008) Evaluation of cytotoxic properties of organometallic ferrocifens on melanocytes, primary and metastatic melanoma cell lines J. Inorg. Biochem. 102, 1980-1985
10. Hillard, E., Vessieres, A., Thouin, L., Jaouen, G., and Amatore, C. (2005) Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast-cancer drug candidates Angew. Chem., Int. Ed. 45, 285-290
11. Franke, J. C., Plotz, M., Prokop, A., Geilen, C. C., Schmalz, H. G., and Eberle, J. (2010) New caspase-independent but ROS-dependent apoptosis pathways are targeted in melanoma cells by an iron-containing cytosine analogue Biochem. Pharmacol. 79, 575-586
12. Dobroschke, M., Geldmacher, Y., Ott, I., Harlos, M., Kater, L., Wagner, L., Gust, R., Sheldrick, W. S., and Prokop, A. (2009) Cytotoxic rhodium(III) and iridium(III) polypyridyl complexes: structure-activity relationships, antileukemic activity, and apoptosis induction ChemMedChem 4, 177-187
13. Bieda, R., Ott, I., Dobroschke, M., Prokop, A., Gust, R., and Sheldrick, W. S. (2009) Structure-activity relationships and DNA binding properties of apoptosis inducing cytotoxic rhodium(III) polypyridyl complexes containing the cyclic thioether [9]aneS(3) J. Inorg. Biochem. 103, 698-708
14. Harlos, M., Ott, I., Gust, R., Alborzinia, H., Wolfl, S., Kromm, A., and Sheldrick, W. S. (2008) Synthesis, biological activity, and structure-activity relationships for potent cytotoxic rhodium(III) polypyridyl complexes J. Med. Chem. 51, 3924-3933
15. Guo, M., Guo, Z., and Sadler, P. J. (2001) Titanium(IV) targets phosphoesters on nucleotides: implications for the mechanism of action of the anticancer drug titanocene dichloride J. Biol. Inorg. Chem. 6, 698-707
16. Tshuva, E. Y. and Peri, D. (2009) Modern cytotoxic titanium(IV) complexes; Insights on the enigmatic involvement of hydrolysis Coord. Chem. Rev. 253, 2098-2115
17. Ott, I., Kircher, B., Bagowski, C. P., Vlecken, D. H., Ott, E. B., Will, J., Bensdorf, K., Sheldrick, W. S., and Gust, R. (2009) Modulation of the biological properties of aspirin by formation of a bioorganometallic derivative Angew. Chem., Int. Ed. 48, 1160-1163
18. Noor, F., Kinscherf, R., Bonaterra, G. A., Walczak, S., Wolfl, S., and Metzler-Nolte, N. (2009) Enhanced cellular uptake and cytotoxicity studies of organometallic bioconjugates of the NLS peptide in Hep G2 cells ChemBioChem 10, 493-502
19. Neundorf, I., Hoyer, J., Splith, K., Rennert, R., Peindy N'dongo, H W., and Schatzschneider, U. (2008) Cymantrene conjugation modulates the intracellular distribution and induces high cytotoxicity of a cell-penetrating peptide Chem. Commun. 5604-5606
20. Joliot, A. and Prochiantz, A. (2004) Transduction peptides: from technology to physiology Nat. Cell Biol. 6, 189-196
21. Pujals, S., Fernandez-Carneado, J., Lopez-Iglesias, C., Kogan, M. J., and Giralt, E. (2006) Mechanistic aspects of CPP-mediated intracellular drug delivery: relevance of CPP self-assembly Biochim. Biophys. Acta 1758, 264-279
22. Chari, R. V. (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs Acc. Chem. Res. 41, 98-107
23. Reddy, L. H. (2005) Drug delivery to tumours: recent strategies J. Pharm. Pharmacol. 57, 1231-1242
24. Law, B. and Tung, C. H. (2009) Proteolysis: a biological process adapted in drug delivery, therapy, and imaging Bioconjugate Chem. 20, 1683-1695
25. Kratz, F., Muller, I. A., Ryppa, C., and Warnecke, A. (2008) Prodrug strategies in anticancer chemotherapy ChemMedChem 3, 20-53
26. Weissleder, R., Tung, C. H., Mahmood, U., and Bogdanov, A., Jr. (1999) In vivo imaging of tumors with protease-activated near-infrared fluorescent probes Nat. Biotechnol. 17, 375-378
27. Funovics, M., Weissleder, R., and Tung, C. H. (2003) Protease sensors for bioimaging Anal. Bioanal. Chem. 377, 956-963
28. Jiang, T., Olson, E. S., Nguyen, Q. T., Roy, M., Jennings, P. A., and Tsien, R. Y. (2004) Tumor imaging by means of proteolytic activation of cell-penetrating peptides Proc. Natl. Acad. Sci. U.S.A. 101, 17867-17872
29. Foekens, J. A., Kos, J., Peters, H. A., Krasovec, M., Look, M. P., Cimerman, N., Meijer-van Gelder, M. E., Henzen-Logmans, S. C., van Putten, W. L., and Klijn, J. G. (1998) Prognostic significance of cathepsins B and L in primary human breast cancer J. Clin. Oncol. 16, 1013-1021
30. Strojnik, T., Kos, J., Zidanik, B., Golouh, R., and Lah, T. (1999) Cathepsin B immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors Clin. Cancer Res. 5, 559-567
31. Miller, K., Erez, R., Segal, E., Shabat, D., and Satchi-Fainaro, R. (2009) Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate Angew. Chem., Int. Ed. 48, 2949-2954
32. van Staveren, D. R. and Metzler-Nolte, N. (2004) Bioorganometallic chemistry of ferrocene Chem. Rev. 104, 5931-5985
33. Husken, N., Gasser, G., Koster, S. D., and Metzler-Nolte, N. (2009) "Four-potential" ferrocene labeling of PNA oligomers via click chemistry Bioconjugate Chem. 20, 1578-1586
34. Hromadova, M., Salmain, M., Fischer-Durand, N., Pospisil, L., and Jaouen, G. (2006) Electrochemical microbead-based immunoassay using an (eta5-cyclopentadienyl)tricarbonylmanganese redox marker bound to bovine serum albumin Langmuir 22, 506-511
35. I Lavastre, J. B., Brossier, P., and Moise, C. (1990) The synthesis of metallocene-labelled drugs for biological assays Appl. Organomet. Chem. 4, 9-17
36. Salmain, M., Fischer-Durand, N., Cavalier, L., Rudolf, B., Zakrzewski, J., and Jaouen, G. (2002) Transition metal-carbonyl labeling of biotin and avidin for use in solid-phase carbonyl metallo immunoassay (CMIA) Bioconjugate Chem. 13, 693-698
37. Splith, K., Neundorf, I., Hu, W., N'Dongo, H., Vasylyeva, V., Merz, K., and Schatzschneider, U. (2010) Influence of the metal complex-to-peptide linker on the synthesis and properties of bioactive CpMn(CO)3 peptide conjugates Dalton Trans. 39, 2536-2545
38. Neundorf, I., Rennert, R., Hoyer, J., Schramm, F., Löbner, K., Kitanovic, I., and Wölfl, S. (2009) Fusion of a short HA2-derived peptide sequence to cell-penetrating peptides improves cytosolic uptake, but enhances cytotoxic activity Pharmaceuticals 2, 49-65
39. Niesel, J., Pinto, A., Peindy N'Dongo, H. W., Merz, K., Ott, I., Gust, R., and Schatzschneider, U. (2008) Photoinduced CO release, cellular uptake and cytotoxicity of a tris(pyrazolyl)methane (tpm) manganese tricarbonyl complex Chem. Commun. 1798-1800
40. Gust, R., Schnurr, B., Krauser, R., Bernhardt, G., Koch, M., Schmid, B., Hummel, E., and Schonenberger, H. (1998) Stability and cellular studies of [rac-1,2-bis(4-fluorophenyl)-ethylenediamine][cyclobutane-1,1- dicarboxylato]platinum(II), a novel, highly active carboplatin derivative J. Cancer Res. Clin. Oncol. 124, 585-597
41. Ott, I., Scheffler, H., and Gust, R. (2007) Development of a method for the quantification of the molar gold concentration in tumour cells exposed to gold-containing drugs ChemMedChem 2, 702-707
42. Kirin, S. I., Ott, I., Gust, R., Mier, W., Weyhermuller, T., and Metzler-Nolte, N. (2008) Cellular uptake quantification of metalated peptide and peptide nucleic acid bioconjugates by atomic absorption spectroscopy Angew. Chem., Int. Ed. 47, 955-959
43. Peindy N'Dongo, H. W., Ott, I., Gust, R., and Schatzschneider, U. (2009) Microwave-assisted solid-phase synthesis, cellular uptake, and cytotoxicity studies of cymantrene-peptide bioconjugates J. Organomet. Chem. 694, 823-827
44. Vermes, I., Haanen, C., Steffens-Nakken, H., and Reutelingsperger, C. (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V J. Immunol. Methods 184, 39-51
45. Chipman, S. D., Oldham, F. B., Pezzoni, G., and Singer, J. W. (2006) Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate Int. J. Nanomedicine 1, 375-383
46. Lutgens, S. P., Cleutjens, K. B., Daemen, M. J., and Heeneman, S. (2007) Cathepsin cysteine proteases in cardiovascular disease FASEB J. 21, 3029-3041 (Pubitemid 47565524)
47. Sardesai, N. Y., Lin, S. C., Zimmerman, K., and Barton, J. K. (1995) Construction of coordinatively saturated rhodium complexes containing appended peptides Bioconjugate Chem. 6, 302-312
48. Pinto, A., Hoffmanns, U., Ott, M., Fricker, G., and Metzler-Nolte, N. (2009) Modification with organometallic compounds improves crossing of the blood-brain barrier of [Leu5]-enkephalin derivatives in an in vitro model system ChemBioChem 10, 1852-1860
49. Noor, F., Wustholz, A., Kinscherf, R., and Metzler-Nolte, N. (2005) A cobaltocenium-peptide bioconjugate shows enhanced cellular uptake and directed nuclear delivery Angew. Chem., Int. Ed. 44, 2429-2432
50. Miklan, Z., Szabo, R., Zsoldos-Mady, V., Remenyi, J., Banoczi, Z., and Hudecz, F. (2007) New ferrocene containing peptide conjugates: synthesis and effect on human leukemia (HL-60) cells Biopolymers 88, 108-114
51. Cosgrave, L., Devocelle, M., Forster, R. J., and Keyes, T. E. (2010) Multimodal cell imaging by ruthenium polypyridyl labelled cell penetrating peptides Chem. Commun. 46, 103-105
52. Erez, R., Segal, E., Miller, K., Satchi-Fainaro, R., and Shabat, D. (2009) Enhanced cytotoxicity of a polymer-drug conjugate with triple payload of paclitaxel Bioorg. Med. Chem. 17, 4327-4335
53. Blanchard, K. T., Clay, R. J., and Morris, J. B. (1996) Pulmonary activation and toxicity of cyclopentadienyl manganese tricarbonyl Toxicol. Appl. Pharmacol. 136, 280-288
54. Krishna, R. and Mayer, L. D. (2000) Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs Eur. J. Pharm. Sci. 11, 265-283